Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
267.5 USD | +1.79% | +0.05% | -7.15% |
Apr. 17 | UBS Adjusts Amgen's Price Target to $284 From $314, Maintains Neutral Rating | MT |
Apr. 16 | Amgen Plans for Phase 3 Trial of Tezepelumab for Lung Disease | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.15% | 141B | |
+24.44% | 672B | |
+24.08% | 550B | |
-5.95% | 351B | |
+15.28% | 317B | |
+6.74% | 292B | |
+3.26% | 211B | |
+0.78% | 203B | |
-9.95% | 144B | |
-3.20% | 113B |
- Stock Market
- Equities
- AMGN Stock
- News Amgen Inc.
- Atlantic Equities Adjusts Amgen's Price Target to $182 from $190, Keeps Underweight Rating